DHT Tubestop Playbook

DHT Tubestop Interactive Map

Navigate the Digital Health Technology lifecycle. Click any Phase Node or Stop Button to access operational deep-dives.

I: Program Planning
  • 1.1 Strategy & Feasibility

    Strategic Plan • Feasibility Enter Stop →
  • 1.2 Procurement & Quality

    Vendor Selection • Quality Agreements Enter Stop →
II: Trial Planning
III: Study Start Up
IV: Study Conduct
V: Closeout
DHT Tubestop

Phase I: Program Planning

Setting the strategic foundation and procurement standards for Digital Health Technology across the clinical development portfolio.

Stop 1.1: Operational Strategy & Feasibility

Defining long-term digital vision and evaluating population-specific technical viability.

Enter Stop

Stop 1.2: Procurement & Quality

Selection and qualification of specialized tech vendors and 21 CFR Part 11 compliance.

Enter Stop
← Back to Phase Hub

Stop 1.1: Operational Strategy & Feasibility

Description

This stop ensures that DHT implementation is treated as a strategic program-level decision rather than a one-off trial gadget. The focus is on aligning technical specifications with the clinical science goals and assessing if the target patient population can successfully interact with the tech.

Substops

1.1.1 Create a DHT Strategic Operations Plan Details →
1.1.2 Conduct DHT Feasibility Assessment Details →

RACI

R Clinical Scientist / Digital Lead
A Head of Clinical Development
C IT, Data Management, Regulatory
I Quality Assurance, Procurement
← Back to Stop 1.1

1.1.1 Create a DHT Strategic Operations Plan

Description

The Strategic Operations Plan acts as the foundational roadmap for DHT use. It defines how digital data will be integrated into the broader data lifecycle and ensures that the technology selected supports the required statistical rigor of the program.

Key Considerations

Context of Use (CoU): Define exactly what the device measures and how it maps to clinical endpoints across the program.
Data Frequency: Determine if high-frequency "raw" data is needed or if processed "metrics" are sufficient for analysis.

References & Citations

CTTI: Digital Health Trials Hub - Planning View

RACI

R Digital Strategy Lead
A Clinical Ops Lead
← Back to Stop 1.1

1.1.2 Conduct DHT Feasibility Assessment

Description

Feasibility assessment involves evaluating the "human side" of the technology. It determines if the intended patients have the technical literacy, infrastructure (Wi-Fi/Cellular), and physical capability to use the device as intended without excessive burden.

Key Considerations

Digital Divide: Assess regional differences in technical access to ensure trial inclusivity and data consistency.
Usability Pitfalls: Early testing can identify issues with battery life, charging requirements, or wearable discomfort.

References & Citations

FDA Guidance: IDE for Early Feasibility Studies View

RACI

R Clinical Scientist / Patient Advocacy
A Clinical Ops Lead
← Back to Phase Hub

Stop 1.2: Procurement & Quality

Description

This stop establishes the framework for selecting and managing DHT vendors. Because the technology and the data it generates are regulated as medical devices and electronic records, vendor qualification must be exceptionally rigorous, focusing on stability, security, and compliance.

Substops

1.2.1 Vendor Selection & Qualification Details →
1.2.2 Contracts & Vendor Management Details →

RACI

R Procurement / Quality Assurance
A Head of Clinical Operations
C Legal, IT Security, Data Management
I Finance
← Back to Stop 1.2

1.2.1 Vendor Selection & Qualification

Description

Identifying vendors who can meet the technical and regulatory requirements of a clinical trial. Audits must confirm 21 CFR Part 11 compliance, data encryption standards, and a robust Quality Management System (QMS).

Key Considerations

Audit Readiness: Does the vendor have documented validation of their hardware and software for clinical use?
Scalability: Can the vendor support the required volume of devices and global data traffic?

References & Citations

FDA: 21 CFR Part 11 - Electronic Records View

RACI

R QA / Clinical Operations
A Procurement Lead
← Back to Stop 1.2

1.2.2 Contracts & Vendor Management

Description

Establishing enforceable agreements that protect the sponsor's data and the participant's privacy. Contracts must clearly define data ownership, service level agreements (SLAs), and the management of firmware or software updates mid-trial.

Key Considerations

Change Management: Contractually mandate notification and approval of any technology updates that could impact data consistency.
Data Portability: Ensure raw data can be retrieved from the vendor at any time and survives vendor termination.

References & Citations

Quality Agreements with Service Providers View Template

RACI

R Legal / Procurement
A Head of Clinical Operations
DHT Tubestop

Phase II: Trial Planning

The design phase where clinical intent meets technical validation. This phase includes the iterative DHT Selection Loop.

Stop 2.0: DHT Selection & Assessment (Loop)

Verification, Analytical Validation, and Clinical Validation (V3) before protocol lock.

Enter Loop

Stop 2.1: Clinical Endpoints Validation

Mapping raw data to meaningful clinical outcomes and patient benefit.

Enter Stop

Stop 2.2: Statistical & Data Planning

Designing data architecture, SAP, and cybersecurity infrastructure.

Enter Stop

Stop 2.3: Protocol Design & Ethics

Integrating DHT procedures and privacy ethics into the master study document.

Enter Stop
← Back to Phase Hub

Stop 2.0: DHT Selection & Assessment (Loop)

Description

This iterative loop is the "Heart" of DHT planning. It ensures that the technology is scientifically sound and regulatory-ready before the protocol is finalized.

Core Requirements: The V3 Framework

  • Verification: Bench testing to confirm hardware/software specs.
  • Analytical Validation: Confirming the algorithm accurately measures the physiological/behavioral parameter.
  • Clinical Validation: Proving the measure is meaningful in the target population.

Watchout: "Context of Use" (CoU). A device validated for heart rate in healthy runners is NOT validated for heart rate in patients with AFib. Validation must match the trial population.

RACI

R Clinical Scientist / Data Scientist
A Medical Director
C Regulatory Affairs / IT
I Clinical Ops
← Back to Phase Hub

Stop 2.1: Clinical Endpoints Validation

Description

This stop defines the scientific purpose of the digital data. We must differentiate between objective biomarkers and patient-focused Clinical Outcome Assessments (COAs).

Critical Planning Steps:

  • Describe clinical meaningfulness from the patient's perspective.
  • Align DHT data (primary vs exploratory) with protocol endpoints.
  • Establish sensitivity/specificity targets for the digital measure.

RACI

R Clinical Scientist
A Medical Director
C Regulatory Affairs
I Biostatistician
← Back to Phase Hub

Stop 2.2: Statistical & Data Planning

Description

High-frequency DHT data requires a specialized architecture. This stop moves from clinical intent to the "Data Pipeline" design.

Technical Deliverables:

  • Data Architecture Diagram: Mapping raw data flow from device to DB.
  • Statistical Analysis Plan (SAP): Defining how to handle missing data and "noise".
  • Cybersecurity Plan: Encryption at rest/transit per ALCOA+ principles.

Watchout: Data Volume. Ensure your database can scale to handle millions of data points without crashing analysis tools.

RACI

R Statistician / Data Manager
A Head of Biostatistics
C IT Security / Clinical Sci
I Clinical Ops
← Back to Phase Hub

Stop 2.3: Protocol Design & Ethics

Description

The final lock. Here, DHT procedures are hard-coded into the study protocol and ethics submissions.

Key Documentation:

  • Intended Use: Defining if DHT data is for safety, primary, or exploratory use.
  • Privacy Ethics: Addressing potential for inducement or over-surveillance.
  • Informed Consent: Transparent language on data access and technical burden.

RACI

R Medical Writer / Clinical Sci
A Medical Director
C Legal / Ethics Committee
I Clinical Ops
DHT Tubestop Lifecycle

Phase III: Study Start Up

Orchestrating the transition from digital strategy to clinical execution. Focus: Quality release, logistics, and site/patient readiness.

Stop 3.1: Documentation Finalization

Approval of SAP/DMP and tech addendums for data integrity.

Enter Stop →

Stop 3.2: Procurement & Logistics

Supply chain management, hardware inspections, and global distribution.

Enter Stop →

Stop 3.3: Site & Patient Enablement

Hands-on training, patient resources, and informed consent execution.

Enter Stop →
← Back to Phase Hub

Stop 3.1: Documentation Finalization

Description

Finalizing the technical and statistical documentation required to ensure DHT data meets ALCOA+ standards. This stop bridges the gap between the study protocol and the actual data management workflows.

Substops

3.1.1 Finalize Statistical Analysis Plan (SAP) Details →
3.1.2 Finalize Data Management Plan (DMP) Details →

Stop RACI

R Statistician / Data Manager
A Medical Director
C Clinical Science / IT
I Clinical Operations
← Back to Stop 3.1

3.1.1 Finalize Statistical Analysis Plan (SAP)

Technical Deep Dive

The SAP must handle high-frequency DHT data by defining the algorithms that transform raw sensor signals into clinical endpoints.

  • Algorithm version lock and validation status.
  • Definition of "Wear Time" compliance (e.g., 10 hrs/day).
  • Imputation rules for missing digital data.

RACI

R Statistician
A Head of Biostatistics
C Clinical Science
I Clinical Ops
← Back to Stop 3.1

3.1.2 Finalize Data Management Plan (DMP)

Technical Deep Dive

Focuses on data architecture, security, and the path from device to database.

  • Encryption at rest (AES-256) and in transit (TLS 1.2).
  • Data reconciliation between device and Subject ID.
  • Audit trail requirements for automated data transfers.

RACI

R Data Manager
A Head of Data Management
C IT Security
I QA
← Back to Phase Hub

Stop 3.2: Procurement & Logistics

Description

The physical mobilization of technology. This stop involves procuring devices, verifying they meet technical standards, and managing the global supply chain.

Substops

3.2.1 Procurement of Devices Details →
3.2.2 First Article Inspection (FAI) Details →
3.2.3 Logistics and Trial Supplies Management Details →

Stop RACI

R Supply Manager / QA
A Head of Clinical Ops
C Vendor Management / Legal
I Finance
← Back to Stop 3.2

3.2.1 Procurement of Devices

Technical Deep Dive

Acquisition of hardware models identified in Phase II. Ensures devices are stock-ready for initial site activation.

  • Inventory buffering for site replacements.
  • Region-specific telecommunication certificates.

RACI

R Procurement Lead
A Head of Clinical Ops
C Finance / Supply Chain
I QA
← Back to Stop 3.2

3.2.2 First Article Inspection (FAI)

Technical Deep Dive

Quality gate to ensure firmware and software pre-loads match technical specifications.

  • Firmware version consistency across serial numbers.
  • Battery performance baseline testing.

RACI

R QA Inspector
A Quality Lead
C Digital Lead
I Procurement
← Back to Stop 3.2

3.2.3 Logistics and Trial Supplies Management

Technical Deep Dive

Global distribution management and reverse logistics for device retrieval or malfunction repair.

  • Customs HS Code identification.
  • Provisioning of prepaid return shipping kits.

RACI

R Supply Chain Manager
A Clinical Ops Lead
C Regulatory (Import/Export)
I Site Staff
← Back to Phase Hub

Stop 3.3: Site & Patient Enablement

Description

Transforming complex technical requirements into actionable human workflows. Focuses on training clinical staff and providing participant resources.

Substops

3.3.1 Create Patient-Facing Materials Details →
3.3.2 Site Set-up and Training Details →
3.3.3 Patient Consent & Oversight Details →

Stop RACI

R Clinical Educator / CRA
A Clinical Ops Lead
C Patient Advocacy / IRB
I Medical Monitor
← Back to Stop 3.3

3.3.1 Create Patient-Facing Materials

Technical Deep Dive

Development of troubleshooting guides and visual manuals for participant success.

  • Step-by-step syncing and charging guides.
  • 6th-8th grade reading level health literacy review.

RACI

R Patient Advocate / Medical Writer
A Clinical Ops Lead
C Digital Lead
I Sites
← Back to Stop 3.3

3.3.2 Site Set-up and Training

Technical Deep Dive

Site Initiation visits including hands-on tech workshops for study coordinators.

  • Coordinator certification on device setup.
  • Site-facing technical manual distribution.

RACI

R CRA / Clinical Trainer
A Clinical Ops Lead
C Digital Lead
I Site PIs
← Back to Stop 3.3

3.3.3 Patient Consent & Oversight

Technical Deep Dive

Ensuring the Informed Consent Form covers digital privacy, data encryption, and device expectations.

  • Clear language on data de-identification.
  • Indication if device provides real-time medical alerts.

RACI

R Site PI / Coordinator
A Clinical Ops Lead
C Ethics Committee / Legal
I Sponsor Quality
DHT Tubestop Lifecycle

Phase IV: Study Conduct

The operational heart of the trial: Real-time oversight of participant adherence, data quality, and management of mid-trial technical updates.

Stop 4.1: Operational Execution & Support

Managing ongoing helpdesks, technical troubleshooting, and safety signal triage.

Enter Stop →

Stop 4.2: Data Monitoring & Compliance

Oversight of data flow quality, participant compliance, and mid-study technology updates.

Enter Stop →
← Back to Phase Hub

Stop 4.1: Operational Execution & Support

Description

Active support for participants and sites to ensure continuous data capture. This stop involves maintaining the technical helpdesk and responding to physiological alerts triggered by DHT data.

Substops

4.1.1 User Support & Technical Troubleshooting Details →
4.1.2 Ongoing Procurement & Supply Management Details →
4.1.3 Safety Reporting & Signal Response Details →

Stop RACI

R Helpdesk / CRA / Supply Manager
A Clinical Ops Lead
C IT / Medical Monitor
I Site Staff
← Back to Stop 4.1

4.1.1 User Support & Technical Troubleshooting

Technical Deep Dive

Maintenance of the 24/7 technical support structure. Effective troubleshooting minimizes "Data Gaps" which can compromise statistical powering.

  • Tiered support desk SLAs (Response within 2-4 hours).
  • Knowledge Base (FAQ) updates based on live participant feedback.
  • Device sync status monitoring.

RACI

R Technical Helpdesk
A Clinical Ops Lead
C Vendor IT
I Participant
← Back to Stop 4.1

4.1.2 Ongoing Procurement & Supply Management

Technical Deep Dive

Managing the flow of replacement devices. Ensures participants receive new hardware within 24-48 hours of a reported failure.

  • Monitoring of "Buffer Stock" levels at sites or central hubs.
  • Refurbishment process for returned faulty hardware.

RACI

R Supply Chain Manager
A Clinical Ops Lead
C Vendor Logistics
I CRA
← Back to Stop 4.1

4.1.3 Safety Reporting & Signal Response

Technical Deep Dive

The workflow for triaging real-time physiological alerts. This stop bridges the gap between digital "noise" and Serious Adverse Events (SAEs).

  • Validation of alert thresholds in the software.
  • Immediate escalation path to the Medical Monitor for "Red Flags."
Watchout: Ensure the helpdesk can distinguish between a technical malfunction (sensor off) and a medical emergency (cardiac event).

RACI

R Medical Monitor / Clin Scientist
A Safety Lead / Medical Director
C Data Manager
I Clinical Ops
← Back to Phase Hub

Stop 4.2: Data Monitoring & Compliance

Description

Oversight of the incoming data stream quality and participant adherence. This stop also manages mid-study technical changes, such as security patches or OS updates.

Substops

4.2.1 Ongoing Data Management & Monitoring Details →
4.2.2 Participant Adherence & Compliance Monitoring Details →
4.2.3 Security Updates & Re-consent Management Details →

Stop RACI

R Data Manager / CRA
A Head of Data Management
C IT Security / Statistician
I Clinical Ops Lead
← Back to Stop 4.2

4.2.1 Ongoing Data Management & Monitoring

Technical Deep Dive

Oversight of automated data transfers. Ensuring that "raw" sensor data is being correctly transformed into "metrics" per the SAP.

  • Audit trail review for data transfers.
  • Cleaning of artifacts or technical noise from the data stream.

RACI

R Data Manager
A Head of Data Management
C CRA / Monitor
I Statistician
← Back to Stop 4.2

4.2.2 Participant Adherence & Compliance Monitoring

Technical Deep Dive

Identifying participants who are not meeting "Wear Time" or "Sync" requirements. Allows for proactive intervention from the site.

  • Review of "Compliance Dashboards."
  • Automated notifications to participants (SMS/Push) for missed syncs.

RACI

R CRA / Central Monitor
A Clinical Ops Lead
C Site Staff
I Medical Monitor
← Back to Stop 4.2

4.2.3 Security Updates & Re-consent Management

Technical Deep Dive

Governance of mid-trial technology changes. Security patches must be deployed without disrupting data collection.

  • Impact assessment for every firmware/app update.
  • Coordination with IRB for updates requiring re-consent.

RACI

R IT Security / Digital Lead
A Clinical Ops Lead
C Legal / Ethics Committee
I Participants
DHT Tubestop Lifecycle

Phase V: Study Closeout & Analysis

The wrap-up phase: Reconciling hardware, locking the digital data stream, and extracting participant insights for future digital strategy.

Stop 5.1: Closeout Activities & Feedback

Device retrieval, supply reconciliation, and gathering participant user experience insights.

Enter Stop →

Stop 5.2: Final Analysis & Reporting

Final statistical execution on digital endpoints and documenting lessons learned.

Enter Stop →
← Back to Phase Hub

Stop 5.1: Closeout Activities & Feedback

Description

This stop manages the "Reverse Logistics" of the DHT lifecycle. It involves the physical retrieval of devices from sites and participants and the reconciliation of inventory against enrollment data.

Substops

5.1.1 Final Procurement & Data Destruction Details →
5.1.2 Supply Reconciliation (DHT Hardware) Details →
5.1.3 Participant Feedback & Engagement Details →

Stop RACI

R CRA / Supply Manager / Data Manager
A Clinical Ops Lead
C QA / IT Security
I Site Staff
← Back to Stop 5.1

5.1.1 Final Procurement & Data Destruction

Technical Deep Dive

Closing the financial and technical loops with the vendor. For DHTs, this involves "Data Destruction" or "Sanitization" of returned hardware to protect patient privacy (GDPR/HIPAA).

  • Certificate of Data Destruction for every returned device serial number.
  • Final vendor payment reconciliation based on device loss/theft rates.
  • Archive of cloud data portals into the Trial Master File (TMF).

RACI

R Procurement / IT Security
A Clinical Ops Lead
C QA
I Legal
← Back to Stop 5.1

5.1.2 Supply Reconciliation (DHT Hardware)

Technical Deep Dive

Physical accounting of all DHT assets. Reconciliation must match the "Procured Amount" vs. "Enrollment Use" vs. "Broken/Lost" units.

  • Reconciliation of site-level inventory logs against central shipping logs.
  • Documentation of "Lost to Follow-up" devices for financial write-off.
  • Shipping confirmation for bulk device returns to refurbish/recycle center.

RACI

R CRA / Supply Manager
A Head of Clinical Ops
C Site Coordinator
I Finance
← Back to Stop 5.1

5.1.3 Participant Feedback & Engagement

Technical Deep Dive

Crucial for future DHT selection. Gathering insights on "Technical Burden"—was the device comfortable, easy to sync, and non-stigmatizing?

  • Analysis of participant satisfaction surveys.
  • Correlation of participant feedback with actual compliance (wear-time) data.
  • Closing the loop with participants: Thank you letters and study result summaries.
Watchout: High attrition in digital trials is often caused by "Friction." Use this data to disqualify specific vendors or devices for future trials.

RACI

R Patient Advocate / Clin Scientist
A Medical Director
C Digital Strategy Lead
I Clinical Ops
← Back to Phase Hub

Stop 5.2: Final Analysis & Reporting

Description

The transition from "Clean Data" to "Clinical Evidence." This stop involves the final statistical processing of digital endpoints and the formal documentation of what went right (and wrong) operationally.

Substops

5.2.1 Final Statistical Analysis Details →
5.2.2 Documenting Lessons Learned Details →

Stop RACI

R Statistician / Clin Scientist
A Medical Director / Head of Stats
C Data Manager / Digital Lead
I Clinical Operations
← Back to Stop 5.2

5.2.1 Final Statistical Analysis

Technical Deep Dive

Execution of the "Algorithm Lock." Processing the full longitudinal digital dataset to determine treatment effect on the digital primary/secondary endpoints.

  • Final imputation of missing data per the SAP.
  • Validation of algorithm performance against any "gold standard" used in Phase II.
  • Preparation of digital data for regulatory submission (SDTM/ADaM datasets).

RACI

R Biostatistician
A Head of Biostatistics
C Data Manager
I Medical Director
← Back to Stop 5.2

5.2.2 Documenting Lessons Learned

Technical Deep Dive

Evaluating the "Tubestop" process. Did the technology choice, logistics provider, and training program meet the study goals? This feeds into the next program-level planning cycle.

  • Analysis of technical support tickets (identifying common device failure points).
  • Vendor Performance Review (SLA adherence).
  • Operational post-mortem report for the Digital Strategy team.

RACI

R Clinical Ops Lead / Digital Lead
A Head of Clinical Development
C QA / Procurement
I Future Trial Teams